ThromboGenics plans to absorb Belgian subsidiary Thromb-X

25-May-2007

ThromboGenics NV announced that it has decided to absorb Thromb-X NV, a wholly-owned subsidiary of ThromboGenics NV. There shall be no issuance of new shares or cash payment upon this transaction. The transaction is expected to be approved at the next Extraordinary General Assembly in July 2007.

Thromb-X is based in Leuven, Belgium, and focuses on the research and development activities of the Group. This decision will enable ThomboGenics to streamline its corporate structure, consolidating its Belgian activities. There will be no impact on the company operations or financials.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...